[go: up one dir, main page]

WO2006119168A3 - Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors - Google Patents

Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors Download PDF

Info

Publication number
WO2006119168A3
WO2006119168A3 PCT/US2006/016590 US2006016590W WO2006119168A3 WO 2006119168 A3 WO2006119168 A3 WO 2006119168A3 US 2006016590 W US2006016590 W US 2006016590W WO 2006119168 A3 WO2006119168 A3 WO 2006119168A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
cox
carotenoids
derivatives
selective inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/016590
Other languages
French (fr)
Other versions
WO2006119168A2 (en
Inventor
Samuel F Lockwood
R Preston Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hawaii Biotech Inc
Original Assignee
Hawaii Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hawaii Biotech Inc filed Critical Hawaii Biotech Inc
Priority to EP06758837A priority Critical patent/EP1890729A2/en
Priority to CA002613169A priority patent/CA2613169A1/en
Publication of WO2006119168A2 publication Critical patent/WO2006119168A2/en
Publication of WO2006119168A3 publication Critical patent/WO2006119168A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.
PCT/US2006/016590 2005-05-02 2006-05-02 Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors Ceased WO2006119168A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06758837A EP1890729A2 (en) 2005-05-02 2006-05-02 Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors
CA002613169A CA2613169A1 (en) 2005-05-02 2006-05-02 Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US67595905P 2005-05-02 2005-05-02
US60/675,959 2005-05-02
US69971705P 2005-07-15 2005-07-15
US60/699,717 2005-07-15
US71845005P 2005-09-19 2005-09-19
US60/718,450 2005-09-19

Publications (2)

Publication Number Publication Date
WO2006119168A2 WO2006119168A2 (en) 2006-11-09
WO2006119168A3 true WO2006119168A3 (en) 2007-01-25

Family

ID=37308576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/016590 Ceased WO2006119168A2 (en) 2005-05-02 2006-05-02 Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors

Country Status (3)

Country Link
EP (1) EP1890729A2 (en)
CA (1) CA2613169A1 (en)
WO (1) WO2006119168A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874289A2 (en) * 2005-03-29 2008-01-09 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
US20070238793A1 (en) * 2005-12-07 2007-10-11 Lockwood Samuel F Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
WO2008106606A2 (en) * 2007-02-28 2008-09-04 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives in the treatment of prostate cancer
US7805004B2 (en) * 2007-02-28 2010-09-28 Microsoft Corporation Radical set determination for HMM based east asian character recognition
AU2015262405B2 (en) 2014-05-20 2019-01-03 Asta Pharmaceuticals Co., Ltd. Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof
CN119504540B (en) * 2024-11-14 2025-08-08 艾迪森生物(青岛)有限公司 Lutein, lutein composition and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061572A2 (en) * 2002-01-16 2003-07-31 David Haines Anti-inflammatory formulations
WO2005002542A2 (en) * 2003-03-03 2005-01-13 Elan Pharma International Ltd. Nanoparticulate meloxican formulations
WO2005009422A1 (en) * 2003-07-16 2005-02-03 Natural Alternatives International, Inc. Anti-inflammatory formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061572A2 (en) * 2002-01-16 2003-07-31 David Haines Anti-inflammatory formulations
WO2005002542A2 (en) * 2003-03-03 2005-01-13 Elan Pharma International Ltd. Nanoparticulate meloxican formulations
WO2005009422A1 (en) * 2003-07-16 2005-02-03 Natural Alternatives International, Inc. Anti-inflammatory formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASON R PRESTON ET AL: "Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2006, vol. 47 Suppl 1, 2006, pages S7 - 14, XP009075108, ISSN: 0160-2446 *

Also Published As

Publication number Publication date
EP1890729A2 (en) 2008-02-27
CA2613169A1 (en) 2006-11-09
WO2006119168A2 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
AU2009221765B2 (en) Compositions and methods for mucositis and oncology therapies
JP2010525050A5 (en)
RU2010104864A (en) SYNERGETIC COMBINATIONS FOR THE TREATMENT OF HYPERTENSION
CR7654A (en) A COMBINATION OF AZELATINE AND STEROIDS
BR0307540A (en) Pharmaceutical preparation in film or lamina form for administering active substances, use of the pharmaceutical preparation and method for the oral administration of bitter-tasting pharmaceutically active substance (s)
EP2374508A1 (en) Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia
Weiss et al. Customized single-agent therapy management of severe inflammatory acne: a randomized, double-blind, parallel-group, controlled study of a new treatment--adapalene 0.3%-benzoyl peroxide 2.5% gel
WO2006119168A3 (en) Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors
KR102602826B1 (en) Biologically-active tomato composition having reduced amount of lycopene
ZA202211148B (en) Use of tetrandrine in combination with all-trans retinoic acid in preparation of medicament for treating pneumoconiosis
KR101891360B1 (en) Medicinal agent for prevention and/or treatment of hepatocellular carcinoma
RU2003122060A (en) CAROTINOIDS AS ANTIHYPERTENSIVE AGENTS
WO2006079900A3 (en) Injection device for administering a medication liquid
WO2007094669A3 (en) Composition used as a nutritional supplement and medication for the treatment of degenerative visual disorders and inflammation
AR048318A1 (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
WO2009037584A3 (en) Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
Khavinson et al. 35-year experience in research of peptide regulation of aging
Zalzala A Novel Approach to Boosting Glutathione via Iontophoresis
Mucalo et al. American ginseng extract (Panax quinquefolius l.) ameliorates glycemic control in type 2 diabetic patients.
LOSS Hormone replacement therapy
Abeywickramal First case of Flegel’s disease in Sri Lanka
Mucalo et al. Effect of American ginseng on arterial stiffness in subjects with well-controlled type-2 diabetes and hypertension.
WO2005120486A3 (en) Novel use of cytotoxic drugs for treatment and prophylasxis of aging diseases by reversing the loss of elasticity of epithelial cells due to aging
Bucolo et al. Research Article Fortified Extract of Red Berry, Ginkgo biloba, and White Willow Bark in Experimental Early Diabetic Retinopathy
UA69269U (en) method for treatment disbacteriosis in patients with herpetic stomatitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006758837

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2613169

Country of ref document: CA